5 Lessons From FDA's First Biosimilar Review
Ringing endorsements by regulators and experts this week for Sandoz Inc.'s biosimilar Zarxio offer key insights into how the U.S. Food and Drug Administration will oversee Big Pharma's next frontier, experts...To view the full article, register now.
Already a subscriber? Click here to view full article